{"release":{"schemaVersion":"maha-epistemic-release/1.0","releaseId":"epirelease_b6a8aae207ba431b909c7f9b1e0bd84c","releaseKind":"initial","status":"active","recordId":"urn:maha:record:genome-editor-delivery-systems","domainSlug":"synthetic-biology","targetSha256":"sha256:96fcae910ef78135fbf36ae41f11fd0fbc6d6ccce6ea326509405f1bb4420fc8","canonicalPath":"/knowledge/synthetic-biology/methods/genome-editor-delivery-systems","canonicalVersion":"1.0.0","supersedesReleaseId":null,"approvals":[{"scope":"boundary-adequacy","reviewId":"epireview_b543118d2b1244da8110f01ff0537f18","reviewSha256":"sha256:60cb071a55a79b88ddac8c002ce06f1c9351b4c98be9f1a88751c3be4ea98518","reviewedAt":"2026-08-30T16:02:00.924Z","reviewerKind":"internal-editorial","reviewMethod":"Each criterion is recomputed from the exact record, its inspected alignment audit, source identity, exact locator, rights basis, claim scope, boundary, uncertainty, replication status, prohibited inferences, and revision digest."},{"scope":"domain-fidelity","reviewId":"epireview_ce07c75a2bdf4851b977e975fc992ab0","reviewSha256":"sha256:89c400578b3f89c621ab1196dc5d5b1e6dda7f1b7d34d634b4366a0c43f1fa95","reviewedAt":"2026-08-30T16:02:00.791Z","reviewerKind":"internal-editorial","reviewMethod":"Each criterion is recomputed from the exact record, its inspected alignment audit, source identity, exact locator, rights basis, claim scope, boundary, uncertainty, replication status, prohibited inferences, and revision digest."},{"scope":"rights-and-locator","reviewId":"epireview_aca0a2ed73244e3c98564baddbaa0053","reviewSha256":"sha256:227bcf62599196bf487272d3fe59f947fcc13ea1b4d853721bfec334b710f761","reviewedAt":"2026-08-30T16:02:01.005Z","reviewerKind":"internal-editorial","reviewMethod":"Each criterion is recomputed from the exact record, its inspected alignment audit, source identity, exact locator, rights basis, claim scope, boundary, uncertainty, replication status, prohibited inferences, and revision digest."},{"scope":"source-fidelity","reviewId":"epireview_fe3dcab2586e471d8bbc1e46f3e7ba3b","reviewSha256":"sha256:488e1befefd9379f9082e69726a136ef477f17226a8488b89e759925d235b25b","reviewedAt":"2026-08-30T16:02:00.681Z","reviewerKind":"internal-editorial","reviewMethod":"Each criterion is recomputed from the exact record, its inspected alignment audit, source identity, exact locator, rights basis, claim scope, boundary, uncertainty, replication status, prohibited inferences, and revision digest."}],"assuranceTier":"internally-reviewed-canonical","releaseAuthority":{"authoritySha256":"sha256:2a0161a3927ae8366af44bda6671b5249802843ff3895dc292c90e5466b88609","attribution":"withheld-by-consent"},"publicChangeSummary":"Initial canonical publication under the disclosed exact-revision internal editorial tier.","recordSha256":"sha256:142ae4fbdceaeeacd9dccb782d8e7f35a59cae6ac3a6153c4ab4e8d781137bbf","gateDecision":{"reasons":[],"recordId":"urn:maha:record:genome-editor-delivery-systems","publicEligible":true,"evaluatedAgainst":"maha-epistemic/1.0"},"releasedAt":"2026-08-30T16:02:44.791Z","releaseSha256":"sha256:12035f137f75a5e315e458acca0ed1877536d2f611ebaf0c682484bfaea663ee","withdrawal":null},"provenance":{"schemaVersion":"maha-epistemic/1.0","evidencePolicyVersion":"mps/0.1","recordId":"urn:maha:record:genome-editor-delivery-systems","canonicalPath":"/knowledge/synthetic-biology/methods/genome-editor-delivery-systems","contentHash":"sha256:142ae4fbdceaeeacd9dccb782d8e7f35a59cae6ac3a6153c4ab4e8d781137bbf","generatedAt":"2026-08-30T16:02:44.791Z","publicationDecision":{"recordId":"urn:maha:record:genome-editor-delivery-systems","publicEligible":true,"evaluatedAgainst":"maha-epistemic/1.0","reasons":[]},"claims":[{"id":"urn:maha:claim:genome-editor-delivery-systems","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.","boundary":"One liver-targeted formulation does not establish delivery to other tissues, repeat dosing, long-term safety, or a general delivery platform.","claimKind":"empirical-claim","sourceIds":["source-gillmore-in-vivo-2021"],"statement":"The cited phase 1 study reports systemic lipid-nanoparticle delivery of Cas9 mRNA and guide RNA to hepatocytes under a named investigational protocol.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-gillmore-in-vivo-2021","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2107454","title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Julian D. Gillmore","Ed Gane","Julian Taubel","Jingzhu Kao","et al."],"boundary":"Early biomarker and safety observations do not establish long-term clinical benefit, rare-event safety, or transfer to other tissues and targets.","publisher":"The New England Journal of Medicine","establishes":"The phase 1 report describes systemic lipid-nanoparticle delivery of CRISPR components and early dose-cohort biomarker and safety observations in adults with transthyretin amyloidosis.","identifiers":[{"value":"10.1056/NEJMoa2107454","scheme":"doi"}],"publishedAt":"2021-06-26","exactLocator":"Abstract; Methods; Results; Figures 1–3; supplementary protocol and statistical analysis.","conflictsOfInterest":"The study was funded by Intellia Therapeutics and Regeneron Pharmaceuticals; author relationships are disclosed."}],"reviewEvents":[{"reviewId":"epireview_fe3dcab2586e471d8bbc1e46f3e7ba3b","scope":"source-fidelity","targetSha256":"sha256:96fcae910ef78135fbf36ae41f11fd0fbc6d6ccce6ea326509405f1bb4420fc8","reviewedAt":"2026-08-30T16:02:00.681Z","verdict":"approve","supersedesReviewId":null},{"reviewId":"epireview_ce07c75a2bdf4851b977e975fc992ab0","scope":"domain-fidelity","targetSha256":"sha256:96fcae910ef78135fbf36ae41f11fd0fbc6d6ccce6ea326509405f1bb4420fc8","reviewedAt":"2026-08-30T16:02:00.791Z","verdict":"approve","supersedesReviewId":null},{"reviewId":"epireview_b543118d2b1244da8110f01ff0537f18","scope":"boundary-adequacy","targetSha256":"sha256:96fcae910ef78135fbf36ae41f11fd0fbc6d6ccce6ea326509405f1bb4420fc8","reviewedAt":"2026-08-30T16:02:00.924Z","verdict":"approve","supersedesReviewId":null},{"reviewId":"epireview_aca0a2ed73244e3c98564baddbaa0053","scope":"rights-and-locator","targetSha256":"sha256:96fcae910ef78135fbf36ae41f11fd0fbc6d6ccce6ea326509405f1bb4420fc8","reviewedAt":"2026-08-30T16:02:01.005Z","verdict":"approve","supersedesReviewId":null}]},"privacyBoundary":"Operational actor fingerprints, bearer credentials, private reviewer profiles, affiliations, conflicts, and non-consented authority identity fields are excluded."}